Maisonneuve, P. et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am. J. Kidney Dis. 35, 157–165 (2000).
J. Am. Soc. Nephrol. 16, 1711–1722 (2005).
Cardiovasc. Therap. 30, 49–59 (2012).
Hostetter, T. Prevention of end-stage renal disease due to type 2 diabetes. N. Engl. J. Med. 345, 910–912 (2001).
Vaish, M. Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol. Cancer 6, 26 (2007).
Arch. Immunol. Therap. Exp. 59, 369–378 (2011).
J. Orthop. Surg. Res. 13, 266 (2018).
Dong, X. et al. Beneficial effects of urine-derived stem cells on fibrosis and apoptosis of myocardial, glomerular and bladder cells. Mol. Cell. Endocrinol. 427, 21–32 (2016).
Transplant. Proc. 44, 1123–1126 (2012).
Imberti, B. et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J. Am. Soc. Nephrol. 18, 2921–2928 (2007).
Togel, F. et al. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev. 18, 475–485 (2009).
Eliopoulos, N. et al. Human marrow-derived mesenchymal stromal cells decrease cisplatin renotoxicity in vitro and in vivo and enhance survival of mice post-intraperitoneal injection. Am. J. Physiol. Ren. Physiol. 299, F1288–F1298 (2010).
Li, Y. et al. Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment. Int. J. Mol. Med. 41, 2629–2639 (2018).
Semedo, P. et al. Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells 27, 3063–3073 (2009).
Diabetes Res. Clin. Pract. 98, 465–473 (2012).
Stem Cells 28, 1446–1455 (2010).
Cell Biol. Int. 38, 497–501 (2014).
Lee, R. H. et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc. Natl Acad. Sci. USA 103, 17438–17443 (2006).
Narayanan, K. et al. Human embryonic stem cells differentiate into functional renal proximal tubular-like cells. Kidney Int. 83, 593–603 (2013).
Yamamoto, M. et al. Branching ducts similar to mesonephric ducts or ureteric buds in teratomas originating from mouse embryonic stem cells. Am. J. Physiol. Ren. Physiol. 290, F52–60 (2006).
Methods Mol. Biol. 826, 179–188 (2012).
Chang, J. W. et al. Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant. 20, 245–257 (2011).
Ezquer, F. E. et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol. Blood Marrow Transplant. 14, 631–640 (2008).
Flaquer, M. et al. Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes. Diabetologia 55, 2059–2068 (2012).
Int. J. Biol. Sci. 6, 499–512 (2010).
Exp. Biol. Med. 236, 1461–1467 (2011).
J. Cell. Physiol. 223, 397–407 (2010).
Togel, F. et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am. J. Physiol. Ren. Physiol. 292, F1626–F1635 (2007).
Fu, Y. et al. Trophic effects of mesenchymal stem cells in tissue regeneration. Tissue Eng. Part B Rev. 23, 515–528 (2017).
Lv, S. et al. Mesenchymal stem cells ameliorate diabetic glomerular fibrosis in vivo and in vitro by inhibiting TGF-beta signalling via secretion of bone morphogenetic protein 7. Diab Vasc. Dis. Res. 11, 251–261 (2014).
Yi, Z. et al. Kidney-targeted transplantation of mesenchymal stem cells by ultrasound-targeted microbubble destruction promotes kidney repair in diabetic nephropathy rats. BioMed. Res. Int. 2013, 526367 (2013).
Methods Mol. Biol. 1024, 19–40 (2013).
J. Cell Biol. 200, 373–383 (2013).
Pancreat. Disord. Ther. 6, e148 (2016).
Kalluri, R. The biology and function of exosomes in cancer. J. Clin. Investig. 126, 1208 (2016).
Am. J. Med. Sci. 356, 481–486 (2018).
Jiang, Z. Z. et al. Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats. Stem Cell Res. Ther. 7, 24 (2016).
Nagaishi, K. et al. Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci. Rep. 6, 34842 (2016).
Fujita, H. et al. Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J. Am. Soc. Nephrolog. 20, 1303–1313 (2009).
Daley, G. Q. From embryos to embryoid bodies: generating blood from embryonic stem cells. Ann. N. Y Acad. Sci. 996, 122–131 (2003).
Methods Enzymol. 365, 287 (2003).
Cell 110, 385–397 (2002).
Nature 292, 154–156 (1981).
Martin, G. R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl Acad. Sci. USA 78, 7634–7638 (1981).
Kobayashi, T. et al. Wnt4-transformed mouse embryonic stem cells differentiate into renal tubular cells. Biochem. Biophys. Res. Commun. 336, 585–595 (2005).
J. Am. Soc. Nephrol. 16, 3527–3534 (2005).
Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).
Proc. Natl Acad. Sci. USA 97, 11307–11312 (2000).
Br. Med. Bull. 116, 19–27 (2015).
Schulz, T. C. Concise review: manufacturing of pancreatic endoderm cells for clinical trials in type 1 diabetes. Stem Cells Transl. Med. 4, 927–931 (2015).
J. Nephrol. 23, 143–146 (2010).
Osafune, K. iPS cell technology-based research for the treatment of diabetic nephropathy. Semin. Nephrol. 32, 479–485 (2012).
Drukker, M. et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 24, 221–229 (2006).
Endocr. Rev. 32, 725 (2011).
Cell 126, 663–676 (2006).
Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920 (2007).
Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
Song, B. et al. The directed differentiation of human iPS cells into kidney podocytes. PloS ONE 7, e46453 (2012).
Lam, A. Q. et al. Rapid and efficient differentiation of human pluripotent stem cells into intermediate mesoderm that forms tubules expressing kidney proximal tubular markers. J. Am. Soc. Nephrol. 25, 1211–1225 (2014).
Xia, Y. et al. The generation of kidney organoids by differentiation of human pluripotent cells to ureteric bud progenitor-like cells. Nat. Protoc. 9, 2693–2704 (2014).
Takasato, M. et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature 536, 238 (2016).
PloS ONE 9, e94888 (2014).
Ciampi, O. et al. Generation of functional podocytes from human induced pluripotent stem cells. Stem Cell Res. 17, 130–139 (2016).
Rogers, I. Induced pluripotent stem cells from human kidney. J. Am. Soc. Nephrol. 22, 1179–1180 (2011).
Song, B. et al. Generation of induced pluripotent stem cells from human kidney mesangial cells. J. Am. Soc. Nephrol. 22, 1213–1220 (2011).
Tajiri, S. et al. Regenerative potential of induced pluripotent stem cells derived from patients undergoing haemodialysis in kidney regeneration. Sci. Rep. 8, 14919 (2018).
Zhou, T. et al. Generation of induced pluripotent stem cells from urine. J. Am. Soc. Nephrol. 22, 1221–1228 (2011).
Nat. Protoc. 13, 1662–1685 (2018).
Feng, Q. et al. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence † ‡ §. Stem Cells 28, 704–712 (2010).
Hu, B. Y. et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl Acad. Sci. USA 107, 4335–4340 (2010).
Wong, R. S. Mesenchymal stem cells: angels or demons? J. Biomed. Biotechnol. 2011, 459510 (2011).
MF, P. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143–147 (1999).
Charbord, P. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum. Gene Ther. 21, 1045–1056 (2010).
Semin. Cell Dev. Biol. 40, 82–88 (2015).
Stem Cells Int. 2018, 9837035 (2018).
Stem Cells 29, 5–10 (2011).
Ezquer, F. et al. Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol. Blood Marrow Transplant. 15, 1354–1365 (2009).
Arch. Med. Res. 47, 71–77 (2016).
Pan, X. H. et al. Bone-marrow mesenchymal stem cell transplantation to treat diabetic nephropathy in tree shrews. Cell Biochem. Funct. 32, 453–463 (2014).
Sun, J. et al. BMSCs and miR-124a ameliorated diabetic nephropathy via inhibiting notch signalling pathway. J. Cell. Mol. Med. 22, 4840–4855 (2018).
Zhou, H. et al. Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats. Chin. Med. J. 122, 2573–2579 (2009).
Lv, S. S. et al. Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting macrophage infiltration. Int. Immunopharmacol. 17, 275–282 (2013).
Lv, S. et al. Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting oxidative stress. Diabetes Res Clin. Pract. 104, 143–154 (2014).
Int. J. Clin. Pract. 59, 1309–1316 (2005).
Biol. Blood Marrow Transplant. 19, 538–546 (2013).
Nagaishi, K. et al. Umbilical cord extracts improve diabetic abnormalities in bone marrow-derived mesenchymal stem cells and increase their therapeutic effects on diabetic nephropathy. Sci. Rep. 7, 8484 (2017).
Noh, H. et al. Uremic toxin p-cresol induces Akt-pathway-selective insulin resistance in bone marrow-derived mesenchymal stem cells. Stem Cells 32, 2443–2453 (2014).
Wu, J. et al. Age-related insulin-like growth factor binding protein-4 overexpression inhibits osteogenic differentiation of rat mesenchymal stem cells. Cell. Physiol. Biochem. 42, 640 (2017).
J. Transl. Med. 9, 10 (2011).
Stem Cells 25, 818–827 (2007).
Ni, W. et al. Adipose-Derived mesenchymal stem cells transplantation alleviates renal injury in streptozotocin-induced diabetic nephropathy. J. Histochem. Cytochem. 63, 842–853 (2015).
de Girolamo, L. et al. Mesenchymal stem/stromal cells: a new “cells as drugs” paradigm. Efficacy and critical aspects in cell therapy. Curr. Pharm. Des. 19, 2459–2473 (2013).
Li, D. et al. Mesenchymal stem cells protect podocytes from apoptosis induced by high glucose via secretion of epithelial growth factor. Stem Cell Res. Ther. 4, 103–103 (2013).
Curr. Stem Cell Res. Ther. 5, 95–102 (2010).
Zhang, L. et al. Repeated systemic administration of human adipose-derived stem cells attenuates overt diabetic nephropathy in rats. Stem Cells Dev. 22, 3074–3086 (2013).
Fang, Y. et al. Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway. Int. J. Mol. Med. 30, 85–92 (2012).
J. Transl. Med. 5, 8 (2007).
Hematol. Am. Soc. Hematol. https://doi.org/10.1182/asheducation-2005.1.377 (2005).
Pharmacol. Rep. 64, 1223–1233 (2012).
Biochem. Biophys. Res. Commun. 321, 168–171 (2004).
Zhang, Y. et al. Urine derived cells are a potential source for urological tissue reconstruction. J. Urol. 180, 2226–2233 (2008).
Bharadwaj, S. et al. Multipotential differentiation of human urine-derived stem cells: potential for therapeutic applications in urology. Stem Cells 31, 1840–1856 (2013).
Ouyang, B. et al. Human urine-derived stem cells alone or genetically-modified with FGF2 Improve type 2 diabetic erectile dysfunction in a rat model. PloS ONE 9, e92825 (2014).
Bharadwaj, S. et al. Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering. Tissue Eng. Part A 17, 2123–2132 (2011).
Science 275, 964 (1997).
Peichev, M. et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 95, 952–958 (2000).
Fadini, G. P. et al. Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 197, 496–503 (2008).
Abe-Yoshio, Y. et al. Involvement of bone marrow-derived endothelial progenitor cells in glomerular capillary repair in habu snake venom-induced glomerulonephritis. Virchows Arch. 453, 97–106 (2008).
Fadini, G. P. et al. Endothelial progenitor cells and the diabetic paradox. Diabetes Care 29, 714–716 (2006).
Makino, H. et al. Decreased circulating CD34 + cells are associated with progression of diabetic nephropathy. Diabet. Med. 26, 171–173 (2009).
Albiero, M. et al. Defective recruitment, survival and proliferation of bone marrow-derived progenitor cells at sites of delayed diabetic wound healing in mice. Diabetologia 54, 945–953 (2011).
Fadini, G. P. et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J. Am. Coll. Cardiol. 45, 1449–1457 (2005).
Bhatwadekar, A. D. et al. Transient inhibition of transforming growth factor-beta1 in human diabetic CD34 + cells enhances vascular reparative functions. Diabetes 59, 2010–2019 (2010).
Leicht, S. F. et al. Adiponectin pretreatment counteracts the detrimental effect of a diabetic environment on endothelial progenitors. Diabetes 60, 652–661 (2011).
Mohler, E. R. III et al. Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol. Cytometry 75, 75–82 (2009).
Pala, C. et al. The effect of diabetes mellitus and end-stage renal disease on the number of CD34 + cells in the blood. Ann. Hematol. 92, 1189–1194 (2013).
Exp. Diabetes Res. 2012, 872504 (2012).
Bahlmann, F. H. et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 64, 1648–1652 (2003).
Mohler, E. R. III et al. Effect of darbepoetin alfa on endothelial progenitor cells and vascular reactivity in chronic kidney disease. Vasc. Med. 16, 183–189 (2011).
Marchac, A. et al. Lp3: endogenous stem cell therapy improves diabetic wound healing. Plast. Reconstruct. Surg. 126, 714–715 (2010).
Uchimura, H. et al. Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis. J. Am. Soc. Nephrol. 16, 997–1004 (2005).
Stem Cells Int. 2016, 1–22 (2016).